Literature DB >> 33754230

Fundamentals of the Dynorphins/Kappa Opioid Receptor System: From Distribution to Signaling and Function.

Catherine Cahill1, Hugo A Tejeda2, Mariana Spetea3, Chongguang Chen4, Lee-Yuan Liu-Chen5.   

Abstract

This chapter provides a general introduction to the dynorphins (DYNs)/kappa opioid receptor (KOR) system, including DYN peptides, neuroanatomy of the DYNs/KOR system, cellular signaling, and in vivo behavioral effects of KOR activation and inhibition. It is intended to serve as a primer for the book and to provide a basic background for the chapters in the book.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  In vivo pharmacology; KOR/dynorphins; Neuroanatomy; Review; Signaling

Mesh：

Substances：

Year:  2022        PMID： 33754230      PMCID： PMC9013522          DOI： 10.1007/164_2021_433

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  113 in total

1.  Focal stimulation of the mossy fibers releases endogenous dynorphins that bind kappa 1-opioid receptors in guinea pig hippocampus.

Authors:  J J Wagner; C J Evans; C Chavkin
Journal:  J Neurochem       Date:  1991-07       Impact factor: 5.372

2.  Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.

Authors:  Yuko Togashi; Hideo Umeuchi; Kiyoshi Okano; Naoki Ando; Yoshitaka Yoshizawa; Toshiyuki Honda; Kuniaki Kawamura; Takashi Endoh; Jun Utsumi; Junzo Kamei; Toshiaki Tanaka; Hiroshi Nagase
Journal:  Eur J Pharmacol       Date:  2002-01-25       Impact factor: 4.432

3.  Sex difference in κ-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig.

Authors:  Yu-Jun Wang; Khampaseuth Rasakham; Peng Huang; Darina Chudnovskaya; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2011-08-12       Impact factor: 4.030

4.  Dynorphins regulate fear memory: from mice to men.

Authors:  Andras Bilkei-Gorzo; Susanne Erk; Britta Schürmann; Daniela Mauer; Kerstin Michel; Henning Boecker; Lukas Scheef; Henrik Walter; Andreas Zimmer
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

5.  The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

Authors:  Kate L White; J Elliott Robinson; Hu Zhu; Jeffrey F DiBerto; Prabhakar R Polepally; Jordan K Zjawiony; David E Nichols; C J Malanga; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-10-15       Impact factor: 4.030

Review 6.  Dynorphin--still an extraordinarily potent opioid peptide.

Authors:  Charles Chavkin
Journal:  Mol Pharmacol       Date:  2012-11-14       Impact factor: 4.436

7.  U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation.

Authors:  J G Li; L Y Luo; J G Krupnick; J L Benovic; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

8.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

10.  Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone.

Authors:  Walter Wittmann; Eduard Schunk; Iris Rosskothen; Stefano Gaburro; Nicolas Singewald; Herbert Herzog; Christoph Schwarzer
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853
View more
  6 in total

1.  In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist.

Authors:  Kristina Puls; Aina-Leonor Olivé-Marti; Szymon Pach; Birgit Pinter; Filippo Erli; Gerhard Wolber; Mariana Spetea
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-28

2.  Agonist-promoted kappa opioid receptor (KOR) phosphorylation has behavioral endpoint-dependent and sex-specific effects.

Authors:  Peng Huang; Chongguang Chen; Danni Cao; Melody Huang; Lee-Yuan Liu-Chen
Journal:  Neuropharmacology       Date:  2021-11-02       Impact factor: 5.273

3.  Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion.

Authors:  Chongguang Chen; Peng Huang; Kathryn Bland; Mengchu Li; Yan Zhang; Lee-Yuan Liu-Chen
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

Review 4.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

Review 5.  Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.

Authors:  Celia García-López; Carmen Gómez-Huertas; José-María Sánchez-González; Davide Borroni; Marina Rodríguez-Calvo-de-Mora; Vito Romano; Rahul Rachwani-Anil; Juan-Francisco Ramos-López; Santiago Ortiz-Pérez; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

6.  Aticaprant (Clinically Developed Kappa-Opioid Receptor Antagonist) Combined With Naltrexone Prevents Alcohol "Relapse" Drinking.

Authors:  Y Zhou; D C Zhou; M J Kreek
Journal:  J Pharm Pharmacol (Los Angel)       Date:  2022-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.